Israel Englander Tg Therapeutics, Inc. Call Options Transaction History

Millennium Management LLC

  • $199 Billion
  • Q3 2024

Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$6.68 - $18.81 $535,068 - $1.51 Million
80,100 Added 78.99%
181,500 $3.1 Million
Q2 2023

Aug 14, 2023
SELL
$15.48 - $35.0 $1.59 Million - $3.61 Million
-103,000 Reduced 50.39%
101,400 $2.52 Million
Q1 2023

May 15, 2023
SELL
$10.23 - $19.34 $479,787 - $907,046
-46,900 Reduced 18.66%
204,400 $3.07 Million
Q4 2022

Feb 14, 2023
BUY
$5.01 - $11.83 $257,013 - $606,879
51,300 Added 25.65%
251,300 $2.97 Million
Q3 2022

Nov 14, 2022
BUY
$4.57 - $8.4 $125,218 - $230,160
27,400 Added 15.87%
200,000 $1.18 Million

Others Institutions Holding TGTX

# of Institutions
340
Shares Held
88.5M
Call Options Held
2.35M
Put Options Held
1.7M
View Full List

About TG THERAPEUTICS, INC.

TGTX Quotes by TradingView
  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $5.09B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email